Subcutaneous versus intravenous tramadol for extremity injury with moderate pain in the emergency department: a randomised controlled noninferiority trial

Bustam, Aida and Poh, Khadijah and Zambri, Aliyah and Mohd Nazri, Mohd Zahir Amin and Subramaniam, Thayaharan and Abdullah, Adlina Athilah and Nor Azman, Amyrul Ikmal Haziq and Ang, Bin Ting and Noor Azhar, Abdul Muhaimin (2023) Subcutaneous versus intravenous tramadol for extremity injury with moderate pain in the emergency department: a randomised controlled noninferiority trial. European Journal of Emergency Medicine, 30 (5). pp. 331-340. ISSN 0969-9546, DOI https://doi.org/10.1097/MEJ.0000000000001047.

Full text not available from this repository.

Abstract

Background and importanceMusculoskeletal trauma is a common presentation in the emergency department (ED). Tramadol as an analgesic has been recommended by pain management guidelines for musculoskeletal pain. Parenteral tramadol in the ED is commonly administered intravenously. Subcutaneously administered tramadol may have other advantages such as easier and faster preparation, avoids the need for intravenous (i.v.) access, and reduces the incidence of respiratory and gastrointestinal effects. However, studies comparing subcutaneous (s.c.) and i.v. tramadol for the management of acute moderate pain in patients with extremity injury are lacking.ObjectiveThe objective of this study was to compare the clinical efficacy of s.c. tramadol vs. i.v. tramadol in patients with moderate pain due to extremity injury in the ED.Design, settings, and participantsThis non-inferiority randomized controlled trial included adult patients presented to an academic, tertiary hospital ED with moderate pain (pain score of 4-6 on the visual analog scale) due to extremity injury. Intervention patients stratified to pain score were randomized to receive 50 mg of i.v. or s.c. tramadol.Outcomes measure and analysisPrimary outcome measure was the difference in the pain score reduction at 30 min after tramadol administration between the two groups. The noninferiority null hypothesis was that the therapeutic difference in terms of pain score reduction of more than 0.8 exists between the two treatment groups at the endpoint.Main resultsIn total 232 patients were randomized to i.v. (n = 115) or s.c. (n = 117). Although 225 were analyzed in the per-protocol population (i.v. = 113; s.c. = 112). The baseline median pain score was 6 (IQR, 5-6). Median pain score reduction at 30 min after administration was 2 (IQR, 1-3) in the IV group vs. 2 (IQR, 1-2) in the s.c. group with a median difference of 0 (IQR, 0-0), which was below the prespecified noninferiority margin of 0.8. Adverse events in the i.v. group were higher compared to the s.c. group (33.6% vs. 8.9%, P & LE; 0.001).ConclusionsThe s.c. tramadol is noninferior to i.v. tramadol in the treatment of moderate pain from extremity injuries.

Item Type: Article
Funders: UNSPECIFIED
Uncontrolled Keywords: emergency department; extremity injury; intravenous; moderate pain; musculoskeletal trauma; non-inferiority trial; subcutaneous; tramadol
Subjects: R Medicine > R Medicine (General)
Divisions: Faculty of Medicine
Depositing User: Ms. Juhaida Abd Rahim
Date Deposited: 08 Sep 2025 04:31
Last Modified: 08 Sep 2025 04:31
URI: http://eprints.um.edu.my/id/eprint/50624

Actions (login required)

View Item View Item